NCT00323310View on ClinicalTrials.gov

Safety and Efficacy of MultiHance in Pediatric Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Central Nervous System Diseases
Interventions
DRUG

gadobenate dimeglumine

A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.

Trial Locations (1)

08540

Bracco Diagnostics, Inc., Princeton

Sponsors
All Listed Sponsors
lead

Bracco Diagnostics, Inc

INDUSTRY